china

Dependence on China for sales, manufacturing or supply, and the trade, policy and economic risks that come with it.

Exposure · 41 companies

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

  • AAPL Apple Inc.

    Exposed“Beginning in Q2 2025, the U.S. announced new tariffs on imports from China mainland, India, Japan, South Korea, Taiwan, Vietnam, the EU and other locations; several countries imposed or threatened reciprocal measures.”

    Latest 8-KDebt financing ·

    Completed a $7.5B senior unsecured notes issuance across floating- and fixed-rate tranches due 2028–2036.

  • AMAT Applied Materials

    Exposed“AMAT’s operations, customers, and suppliers are globally distributed, with particular exposure to China, Taiwan, and Korea.”

    Latest 8-KPositiveEarningsNew guidanceLegal / investigation ·

    AI-driven chip demand lifts Semiconductor Systems; Q1 revenue guide midpoint of $11.1B tops Q4.

  • Latest 424B4final IPO prospectusMixedBankruptcy / going concernAccounting issueCustomer concentration ·

    Titanium and refractory metal powder maker scales up for defense and aerospace; IPO funding extends runway only into Q2 2027

  • AMZN Amazon

    Exposed“China-based sellers contribute significant third-party seller services and advertising revenue, while China-based suppliers provide significant components and finished goods, increasing exposure to trade restrictions, tariffs, geopolitical events, and other China-related disruptions.”

    Latest 10-QQ3 FY2026Mixed ·

    AWS growth accelerates as OpenAI and Anthropic ties deepen; AI infrastructure spending outpaces operating cash generation.

    • Revenue$201.9BYoY +12.1%
    • Net income$20.7BYoY −2.4%
  • APH Amphenol

    Exposed“a previously disclosed $160.0 additional China tax obligation.”

    Latest 10-QQ3 FY2026Positive ·

    AI data communications demand accelerates organic growth as CommScope adds scale; acquisition financing and tax charges temper earnings gains.

    • Revenue$10.2BYoY +65.1%
    • Net income$2.0BYoY +63.3%
  • ATTO Attovia Therapeutics, Inc.

    Exposed“WuXi AppTec was added to the 1260H List on June 8, 2026; the effect of BIOSECURE Act restrictions and grandfathering remained uncertain, and WuXi Biologics was not then on the list.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops immune-disease biologics using ATTOBODY; $289M all-primary raise backs clinical validation of itch treatment ATTO-1310.

  • BBTX Bambusa Therapeutics, Inc.

    Exposed“Reliance on China-based providers, including WuXi Biologics, BioNTech Zhuhai and Tigermed, exposes development and supply to political, regulatory, trade, currency and IP risks.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernAccounting issueImpairment / charge ·

    Develops dual-target antibodies for eczema and respiratory diseases; $169M raise funds trials of BBT001 and BBT002.

  • BLSM BlossomHill Therapeutics, Inc.

    Exposed“APIs for BH-30643 and BH-30236 are made in China, although candidate drug product is not currently manufactured there; the company is pursuing alternative suppliers outside China.”

    Latest 424B4final IPO prospectusBankruptcy / going concernPre-revenue ·

    Develops small-molecule cancer drugs; $150M all-primary raise funds trials led by BH-30643 for treatment-resistant lung cancer.

  • BRKR Bruker

    Exposed“Delayed Chinese government stimulus for high-end medical and industrial research instrumentation constrained growth.”

    Latest 8-KLeadership change ·

    Board adds immunologist Eicke Latz as life-science work expands; declares $0.05/share quarterly dividend.

  • BRVE Braveheart Bio, Inc.

    Exposed“U.S.–China tensions, trade restrictions, tariffs, sanctions, data rules and other policy changes could disrupt supply, trials or the Hengrui relationship.”

    Latest 424B4final IPO prospectusPositiveImpairment / chargePre-revenueRelated-party dependence ·

    Develops BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy; $383M all-primary raise funds Phase 3 trials.

  • BSX Boston Scientific

    Exposed“Other pressures included increased Electrophysiology competition and slower LAAC market growth affecting WATCHMAN procedures, as well as China volume-based procurement effects in Endoscopy and Urology.”

    Latest 8-KLeadership changeExecutive pay ·

    David S. Wichmann to succeed Ludwig as lead independent director; 2027 executive incentives tie payouts to sales, adjusted EPS and shareholder returns

  • CDNS Cadence Design Systems

    Exposed“Cadence identifies U.S.–China tensions and Taiwan’s role in the technology supply chain as significant exposures.”

    Latest 10-QQ3 FY2026PositiveRestructuring ·

    Hexagon deal broadens system-level engineering, but acquisition costs and higher investment keep operating profit flat despite strong sales growth.

    • Revenue$1.6BYoY +22.0%
    • Net income$289.7MYoY +0.9%
  • CI Cigna Group

    Exposed“Cigna’s 50% share of the China insurance joint venture’s supporting portfolio was approximately $21.9B, about 75% debt securities, 20% equities and 5% long-term deposits and policy loans;”

    Latest 10-QQ3 FY2026MixedRestructuring ·

    Rebate-free investment and contract renewals squeeze Evernorth’s pharmacy-benefit earnings; specialty care provides an offset.

    • Revenue$73.7BYoY +5.6%
    • Net income$1.4BYoY −22.8%
  • CSCO Cisco

    Exposed“Macroeconomic and geopolitical conditions—including inflation, tariffs and trade restrictions, monetary-policy uncertainty, government disruptions, conflicts, and China-Taiwan tensions—could constrain IT spending, disrupt supply, increase costs, intensify price competition, and create excess inventory or capacity.”

    Latest 10-QQ1 FY2027PositiveRestructuring ·

    Silicon One and optics drive an AI-led hardware surge, but subscriptions lag as supplier commitments climb.

    • Revenue$18.5BYoY +24.4%
    • Net income$4.6BYoY +59.2%
  • CTVA Corteva

    Exposed“A material portion of crop-protection inputs comes directly or indirectly from China.”

    Latest 8-KNegativeGuidance loweredRestructuringImpairment / charge ·

    Seed separation makes Vylor independent; FY2026 operating EBITDA guidance lowered to $1.10B–$1.125B

  • EMR Emerson Electric

    Exposed“Sales by geographic destination in 2026 were: the Americas, 52 percent; Asia, Middle East & Africa, 30 percent (China, 9 percent); and Europe, 18 percent .”

    Latest 8-KDebt financing ·

    Completed a €750M public offering of 4% senior unsecured notes.

  • FOIL Londian Wason New Energy Tech Inc.

    Exposed“Substantially all operations and revenue are generated in China, exposing FOIL to PRC economic, political, legal and regulatory changes.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernCustomer concentrationControlled company ·

    Makes copper foil for batteries and electronics; chairman Guanran Wang retains 51.3% control after the offering.

  • FSLR First Solar

    Exposed“The company is realigning Series 6 production at international facilities amid low-priced Chinese competition in Europe, India’s restrictions on Southeast Asian products, regional oversupply and U.S. import tariffs.”

    Latest 10-QQ3 FY2026Legal / investigation ·

    Section 45X credits lift profits despite weaker module shipments, but delayed collections and rising inventory strain cash flow.

    • Revenue$1.2BYoY −22.8%
    • Net income$571.1MYoY +25.2%
  • GM General Motors

    Exposed“Automotive China JVs, whose vehicle sales are not included in GM revenue, reported Q3 revenue of **$6.649B from $6.121B** and net income of **$0.141B from $0.144B**.”

    Latest 8-KLeadership change ·

    Chief Accounting Officer Christopher T. Hatto plans to retire April 1, 2027, remaining principal accounting officer through that date.

  • ISRG Intuitive Surgical

    Exposed“In China, provincial limits on charges for robotic-assisted surgery have reduced procedure volumes and pressured instruments-and-accessories pricing.”

    Latest 8-KLeadership change ·

    Humana insurance chief Aaron Martin appointed independent director, expanding the board effective Jan. 1, 2027.

  • KEYS Keysight Technologies

    Exposed“Tariff increases announced beginning in fiscal Q2 2025, including higher rates on China, and retaliatory measures have added uncertainty and may raise costs, disrupt supply chains, and reduce customer demand.”

    Latest 8-KPositiveEarningsNew guidance ·

    Commercial communications drove faster growth; Q1 FY2027 revenue guided to $2.04B–$2.06B.

  • KLAC KLA Corporation

    Exposed“China is a major source of revenue, although its share declined to 30% of FY2026 revenue, from 33% in FY2025 and 43% in FY2024; KLA expects it may decline further.”

    Latest 8-KShareholder voteLeadership change ·

    Board declared a $0.23/share quarterly dividend payable Dec. 1; Jason Conley’s board term ended after he did not seek re-election.

  • LRCX Lam Research

    Exposed“China accounted for **34% of FY2026 revenue, 34% in FY2025, and 42% in FY2024**.”

    Latest 8-KPositiveShareholder voteBuyback ·

    Authorizes up to $25B in buybacks and declares a $0.33/share quarterly dividend, citing cash generation.

  • MPWR Monolithic Power Systems

    Exposed“China and Taiwan together represented the majority of Q3 revenue.”

    Latest 10-QQ3 FY2026PositiveAccounting issue ·

    AI server and optical-networking power demand accelerate growth; rising inventory and capacity spending constrain cash generation.

    • Revenue$1.2BYoY +63.1%
    • Net income$271.1MYoY +50.8%
  • MRK Merck & Co.

    Exposed“Gardasil/Gardasil 9 sales in China fell significantly in 2025.”

    Latest 8-KLeadership change ·

    Douglas M. Baker Jr. succeeds Thomas H. Glocer as independent lead director Jan. 1, 2027, ahead of Glocer’s May 2027 board retirement.

  • MRVL Marvell Technology

    Exposed“Shipments to China represented **42%** of Q2 revenue (**$1.1615B**) and **43%** of H1 (**$2.2194B**), compared with 29% (**$583.4M**) and 33% (**$1.2923B**) a year earlier.”

    Latest 8-KLeadership change ·

    Board expands from seven to ten as Morris, Goodarzi and Bettinger join, adding talent strategy, finance and semiconductor leadership experience.

  • MW Tailored Brands, Inc. / DE

    Exposed“In FY2025, direct product sourcing was concentrated in Vietnam (24%), Indonesia (14%), Bangladesh (11%) and China (11%).”

    Latest S-1/Aamended IPO prospectusAccounting issueControlled company ·

    Menswear and formalwear rental retailer behind Men’s Wearhouse; offering funds debt repayment after shareholder payouts.

  • NET Cloudflare

    Exposed“In China, network services depend substantially on JD Cloud; losing the relationship could impair service utility and results.”

    Latest 10-QQ3 FY2026PositiveRestructuring ·

    Enterprise expansion accelerates growth as Cloudflare builds AI capacity; higher network costs and compensation widen GAAP losses.

    • Revenue$782.5MYoY +39.2%
    • Net income−$34.1Mvs −$1.3M year ago
  • NKE Nike

    Exposed“Greater China revenue declined 13% currency-neutral, with footwear units down 14% and digital sales down 29%.”

    Latest 8-KLeadership change ·

    Mónica Gil resigned from the Board and Compensation Committee; the Board will shrink to 11 directors.

  • NVDA Nvidia

    Exposed“As of the end of fiscal year 2026, we were effectively foreclosed from competing in China's data center computing/compute market, and our effective foreclosure from the China market helped our competitors build larger developer and customer ecosystems to challenge us worldwide.”

    Latest 8-KPositiveEarningsNew guidanceImpairment / charge ·

    Vera Rubin ramp accelerates revenue growth but pressures Q4 margins; Q4 revenue guided to $126.1B–$133.9B.

  • QCOM Qualcomm

    Exposed“China, including Hong Kong, accounted for $18.079B (42%) of revenue, down from $20.340B (46%); these figures reflect customer/licensee headquarters, not necessarily end-device sales locations.”

    Latest 8-KDebt financing ·

    Enters $4.0B senior unsecured note offering across five fixed-rate tranches maturing from 2028 to 2036.

  • SMCI Supermicro

    Exposed“As a result of regulatory changes, we may be required to obtain licenses or other authorizations to continue supporting existing customers or to supply existing products to new customers in China, Eastern Europe, Southeast Asia, and elsewhere.”

    Latest 10-QQ1 FY2027MixedAccounting issue ·

    GB200 and GB300 shipments accelerated and richer mix lifted margins; inventory and receivables kept operating cash flow negative.

    • Revenue$19.9Bvs $5.0B year ago
    • Net income$1.6Bvs $168.3M year ago
  • SNOW Snowflake Inc.

    Exposed“In China, local law requires use of a Chinese-owned operating partner that controls certain aspects of operations and acts as seller of record, adding cost and partner, regulatory and geopolitical risk.”

    Latest 8-KDebt financing ·

    Closed an upsized $3.75B zero-coupon convertible offering to fund capped calls and repurchase some 2027 notes.

  • SYTN Syntiant Corp.

    Exposed“Our two manufacturing facilities in Suzhou, China and Penang, Malaysia provide exclusive assembly and test operations for our sensor business, supporting high-volume production of our SiSonic MEMS microphones, vibration sensors, and AISonic audio DSP products.”

    Latest S-1/Aamended IPO prospectusNegativeCustomer concentration ·

    Sells microphones and on-device AI chips; acquired Knowles operations supplied 97% of FY2025 revenue.

  • TEL TE Connectivity

    Exposed“TE has 19 principal manufacturing sites in China, and approximately 25% of FY2026 net sales were to customers in China; U.S.–China tensions, tariffs, restrictions, regulatory changes, or local-law issues could affect operations and sales.”

    Latest 10-KFY2026Positive ·

    AI data-center and grid demand made Industrial Solutions the largest operating-profit contributor, reducing reliance on automotive.

    • Revenue$19.9BYoY +15.2%
    • Net income$3.3BYoY +76.6%
  • TMO Thermo Fisher Scientific

    Exposed“Growth across pharma and biotech, industrial and applied markets, and North America, Europe and Asia-Pacific was partly offset by lower revenue in China.”

    Latest 8-KLeadership change ·

    Executive Vice President Michael D. Shafer will retire effective Dec. 31, 2026.

  • TXN Texas Instruments

    Exposed“China revenue increased from $1.019 billion; Germany accounted for 9% of revenue, down from 10%.”

    Latest 8-KDebt financing ·

    Completed a $2.0B senior notes issuance, split equally across four maturities from 2028 to 2036.

  • UUUU ENERGY FUELS INC

    Exposed“REE demand is supported by magnets used in EVs, robotics, energy and defense, but markets and supply chains remain volatile and China-centered.”

    Latest 8-KPositiveGuidance ·

    Completed ASM acquisition adds rare earth metals and alloys; pending VAC deal would add magnet manufacturing to the U.S.-centered mine-to-magnet push.

  • VAT VARSAL TECH, INC.

    Exposed“VAT depends on two third-party facilities in China for substantially all of its products, under exclusive custom-manufacturing arrangements.”

    Latest S-1/Aamended IPO prospectusAccounting issueCustomer concentration ·

    Supplies pharmaceutical intermediates from Chinese manufacturers; existing holders retain 98.5% of post-IPO votes

  • WDC Western Digital

    Exposed“The filing highlights Middle East tensions and China’s restrictions on rare earth minerals and related materials important to semiconductor and hard-drive manufacturing.”

    Latest 8-KDebt financing ·

    New $1.5B unsecured revolver replaces prior loan agreement; all outstanding amounts under the old agreement were repaid.

  • WWB WINDWARD BIO GROUP AG

    Exposed“PRC-related policy, geopolitical, export-control, sanctions, or data-transfer restrictions could disrupt access to data, technology, materials, manufacturing, or support.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops long-acting antibodies for asthma and other inflammatory diseases; $175M raise funds trials led by WIN378’s potential twice-yearly dosing

Feedback